A letter to the editor is presented in response to the article "OPTIMIZE Trial Investigators: Three vs. twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial," by Fausto Feres, Ricardo A. Acosta, Deepak L. Bhatt and others, published in the December 18, 2013 issue.